Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia
Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia
复制标题
DOI：
10.1038/sj.leu.2404975
复制
发表时间：
2007-12-01
期刊：
影响因子：
11.4
通讯作者：
Borregaard, N.
中科院分区：
文献类型：
--
作者：
Niemann, C. U.;Kjeldsen, L.;Borregaard, N.
Serglycin 是造血细胞的主要细胞相关蛋白多糖。先前的研究表明，血清甘氨酸可能参与将某些蛋白质靶向细胞毒性淋巴细胞、肥大细胞和中性粒细胞的颗粒。我们通过免疫组织化学和 ELISA 表征了血清甘氨酸在各种血液恶性肿瘤中的表达。发现血清甘氨酸表达可区分急性髓细胞白血病 (AML) 和急性淋巴细胞白血病。与髓过氧化物酶相反，丝甘氨酸被发现是未成熟骨髓细胞的选择性标记物，可将 AML 与费城染色体阴性慢性骨髓增殖性疾病区分开来。
Serglycin is the major cell-associated proteoglycan of hematopoietic cells. Previous work has demonstrated that serglycin may be involved in targeting some proteins to granules of cytotoxic lymphocytes, mast cells and neutrophils. We characterized the expression of serglycin in various hematologic malignancies by immunohistochemistry and ELISA. Serglycin expression was found to distinguish acute myeloid leukemia (AML) from acute lymphoblastic leukemia. In contrast to myeloperoxidase, serglycin was found to be a selective marker for immature myeloid cells, distinguishing AML from Philadelphia chromosome-negative chronic myeloproliferative disorders.